Verrica Pharmaceuticals Inc (NASDAQ: VRCA) kicked off on Friday, down -3.78% from the previous trading day, before settling in for the closing price of $2.91. Over the past 52 weeks, VRCA has traded in a range of $2.72-$11.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -13.60% over the past five years. While this was happening, its average annual earnings per share was recorded -1.61%. With a float of $25.91 million, this company’s outstanding shares have now reached $42.41 million.
Let’s look at the performance matrix of the company that is accounted for 100 employees. In terms of profitability, gross margin is 84.14%, operating margin of -563.14%, and the pretax margin is -625.06%.
Verrica Pharmaceuticals Inc (VRCA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verrica Pharmaceuticals Inc is 39.28%, while institutional ownership is 43.77%. The most recent insider transaction that took place on Jul 22 ’24, was worth 229,231. In this transaction PRESIDENT AND CEO of this company sold 32,469 shares at a rate of $7.06, taking the stock ownership to the 250,121 shares. Before that another transaction happened on Jul 23 ’24, when Company’s PRESIDENT AND CEO sold 154 for $6.98, making the entire transaction worth $1,075. This insider now owns 249,967 shares in total.
Verrica Pharmaceuticals Inc (VRCA) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.54 earnings per share (EPS), lower than consensus estimate (set at -0.36) by -0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.61% per share during the next fiscal year.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Trading Performance Indicators
Take a look at Verrica Pharmaceuticals Inc’s (VRCA) current performance indicators. Last quarter, stock had a quick ratio of 2.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.88, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -0.90 in one year’s time.
Technical Analysis of Verrica Pharmaceuticals Inc (VRCA)
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) saw its 5-day average volume 2.29 million, a positive change from its year-to-date volume of 0.26 million. As of the previous 9 days, the stock’s Stochastic%D was 4.36%. Additionally, its Average True Range was 0.66.
During the past 100 days, Verrica Pharmaceuticals Inc’s (VRCA) raw stochastic average was set at 1.15%, which indicates a significant decrease from 2.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 204.16% in the past 14 days, which was higher than the 108.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.01, while its 200-day Moving Average is $6.13. Nevertheless, the first resistance level for the watch stands at $2.89 in the near term. At $2.99, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.08. If the price goes on to break the first support level at $2.70, it is likely to go to the next support level at $2.61. Assuming the price breaks the second support level, the third support level stands at $2.51.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Key Stats
The company with the Market Capitalisation of 119.48 million has total of 42,420K Shares Outstanding. Its annual sales at the moment are 5,120 K in contrast with the sum of -67,000 K annual income. Company’s last quarter sales were recorded 3,830 K and last quarter income was -20,330 K.
